Accordingly, blocking this interaction with the CTLA-4-Ig fusion protein Abatacept (CTLA-4 binds to CD80 and CD86 with a greater affinity and avidity than CD28) reduces the incidence of GVHD in patients [152, 153]. The gene discussed is CD80; the disease is graft versus host disease.